Alkermes plc (8AK) - Total Liabilities
Based on the latest financial reports, Alkermes plc (8AK) has total liabilities worth €2.51 Billion EUR (≈ $2.93 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alkermes plc - Total Liabilities Trend (2013–2025)
This chart illustrates how Alkermes plc's total liabilities have evolved over time, based on quarterly financial data. See Alkermes plc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Alkermes plc Competitors by Total Liabilities
The table below lists competitors of Alkermes plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pampa Energia SA
BA:PAMP
|
Argentina | AR$3.23 Billion |
|
Shenzhen Zhongjin Lingnan Nonfemet Co Ltd
SHE:000060
|
China | CN¥31.14 Billion |
|
Shandong Xinchao Energy Co Ltd
SHG:600777
|
China | CN¥12.30 Billion |
|
WG Tech JiangXi Co Ltd
SHG:603773
|
China | CN¥3.00 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥831.98 Million |
|
Meritage Corporation
NYSE:MTH
|
USA | $2.47 Billion |
|
Scout24 AG
XETRA:G24
|
Germany | €737.38 Million |
|
Firefly Aerospace Inc. Common Stock
NASDAQ:FLY
|
USA | $387.11 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Alkermes plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Alkermes plc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alkermes plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alkermes plc (2013–2025)
The table below shows the annual total liabilities of Alkermes plc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €667.70 Million ≈ $780.61 Million |
+13.06% |
| 2024-12-31 | €590.59 Million ≈ $690.46 Million |
-36.74% |
| 2023-12-31 | €933.54 Million ≈ $1.09 Billion |
+1.45% |
| 2022-12-31 | €920.23 Million ≈ $1.08 Billion |
+0.91% |
| 2021-12-31 | €911.90 Million ≈ $1.07 Billion |
+39.49% |
| 2018-12-31 | €653.72 Million ≈ $764.27 Million |
+9.98% |
| 2017-12-31 | €594.42 Million ≈ $694.94 Million |
+14.99% |
| 2016-12-31 | €516.94 Million ≈ $604.36 Million |
-4.53% |
| 2015-12-31 | €541.47 Million ≈ $633.03 Million |
+3.69% |
| 2014-12-31 | €522.22 Million ≈ $610.53 Million |
+1.92% |
| 2013-12-31 | €512.40 Million ≈ $599.05 Million |
-- |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more